Nasus Pharma
NSRX
9 hedge funds and large institutions have $7.84M invested in Nasus Pharma in 2026 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0.23% less ownership
Funds ownership: 18.36% → 18.13% (-0.23%)
10% less funds holding
Funds holding: 10 → 9 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
69% less capital inflows, than outflows
Capital inflows: $41.9K | Capital outflows: $135K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$8.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$77K |
| 2 |
XTX Topco
George Town,
Cayman Islands
|
-$58.2K |
NSRX Hedge Fund Activity: Q3 2026 in Review
9 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in Nasus Pharma (NSRX) for Q3 2026, worth a combined $7.84M — up 4.1% from $7.53M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of NSRX and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $8.3K. The largest seller was Citadel Advisors, exiting entirely with an estimated $77K sold.
- 9 institutional investors held Nasus Pharma (NSRX) as of Q3 2026, down from 10 in Q2 2026.
- Funds reported $7.84M of Nasus Pharma stock for Q3 2026, up 4.1% quarter-over-quarter.
- 1 fund opened new Nasus Pharma positions in Q3 2026 and 2 closed out, a net change of -1 holder.
- The largest Nasus Pharma buyer in Q3 2026 was Renaissance Technologies, an estimated $8.3K added.
- The largest Nasus Pharma seller in Q3 2026 was Citadel Advisors, an estimated $77K sold.
Based on aggregated 13F filings for Q3 2026.